Jump to content
 







Main menu
   


Navigation  



Main page
Contents
Current events
Random article
About Wikipedia
Contact us
Donate
 




Contribute  



Help
Learn to edit
Community portal
Recent changes
Upload file
 








Search  

































Create account

Log in
 









Create account
 Log in
 




Pages for logged out editors learn more  



Contributions
Talk
 



















Contents

   



(Top)
 


1 References  














Dotarizine






Русский
Српски / srpski
Srpskohrvatski / српскохрватски
Türkçe
Tiếng Vit
 

Edit links
 









Article
Talk
 

















Read
Edit
View history
 








Tools
   


Actions  



Read
Edit
View history
 




General  



What links here
Related changes
Upload file
Special pages
Permanent link
Page information
Cite this page
Get shortened URL
Download QR code
Wikidata item
 




Print/export  



Download as PDF
Printable version
 
















Appearance
   

 






From Wikipedia, the free encyclopedia
 


Dotarizine
Clinical data
Other namesDotarizine
ATC code
  • none
Identifiers
  • 1-[diphenylmethyl]-4-[3-(2-phenyl-1,3-dioxolan-2-yl)propyl]piperazine

CAS Number
PubChem CID
ChemSpider
UNII
ChEBI
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC29H34N2O2
Molar mass442.603 g·mol−1
3D model (JSmol)
  • C1CN(CCN1CCCC2(OCCO2)C3=CC=CC=C3)C(C4=CC=CC=C4)C5=CC=CC=C5

  • InChI=1S/C29H34N2O2/c1-4-11-25(12-5-1)28(26-13-6-2-7-14-26)31-21-19-30(20-22-31)18-10-17-29(32-23-24-33-29)27-15-8-3-9-16-27/h1-9,11-16,28H,10,17-24H2 ☒N

  • Key:LRMJAFKKJLRDLE-UHFFFAOYSA-N ☒N

 ☒NcheckY (what is this?)  (verify)

Dotarizine is a drug used in the treatment of migraine,[1] which acts as a calcium channel blocker,[2] and also as an antagonist at the 5HT2A receptor, and to a lesser extent at the 5HT1A and 5HT2C receptors.[3][4] The anti-migraine action is thought to be due to its action as a vasodilator,[5][6] but it also has some anxiolytic effects[7] and blocks amnesia produced by electroconvulsive shock in animals.[8]

References[edit]

  1. ^ Ruiz-Nuño A, Villarroya M, Cano-Abad M, Rosado A, Balfagón G, López MG, García AG (January 2001). "Mechanisms of blockade by the novel migraine prophylactic agent, dotarizine, of various brain and peripheral vessel contractility". European Journal of Pharmacology. 411 (3): 289–99. doi:10.1016/S0014-2999(00)00897-9. PMID 11164387.
  • ^ Ruiz-Nuño A, Mayorgas I, Hernández-Guijo JM, Olivares R, García AG, Gandía L (November 2003). "Antimigraine dotarizine blocks P/Q Ca2+ channels and exocytosis in a voltage-dependent manner in chromaffin cells". European Journal of Pharmacology. 481 (1): 41–50. doi:10.1016/j.ejphar.2003.09.013. PMID 14637173.
  • ^ Farré M, Roset PN, Llorente M, Márquez M, Albet C, Pérez JA, et al. (June 1997). "Clinical pharmacokinetics and tolerability of dotarizine in healthy subjects after single and multiple oral administration". Methods and Findings in Experimental and Clinical Pharmacology. 19 (5): 343–50. PMID 9379783.
  • ^ Montiel C, Herrero CJ, García-Palomero E, Renart J, García AG, Lomax RB (August 1997). "Serotonergic effects of dotarizine in coronary artery and in oocytes expressing 5-HT2 receptors". European Journal of Pharmacology. 332 (2): 183–93. doi:10.1016/S0014-2999(97)01073-X. PMID 9286620.
  • ^ Kuridze N, Gajkowska B, Czernicki Z, Jurkiewicz J, Cervos-Navarro J (1998). "The effect of Dotarizine--(Ca2+ channel blocker)--on vascular reactivity and ultrastructure of cerebral capillaries in animals subjected to anoxia". Folia Neuropathologica. 36 (2): 101–8. PMID 9757621.
  • ^ Kuridze N, Czernicki Z, Jarus-Dziedzic K, Jurkiewicz J, Cervos-Navarro J (April 2000). "Regional differences of cerebrovascular reactivity effected by calcium channel blocker - dotarizine". Journal of the Neurological Sciences. 175 (1): 13–6. doi:10.1016/S0022-510X(00)00275-6. PMID 10785251. S2CID 30117433.
  • ^ Petkov VD, Belcheva S, Konstantinova E (December 1995). "Anxiolytic effects of dotarizine, a possible antimigraine drug". Methods and Findings in Experimental and Clinical Pharmacology. 17 (10): 659–68. PMID 9053586.
  • ^ Lazarova M, Petkova B, Petkov VD (1995). "Effect of dotarizine on electroconvulsive shock or pentylenetetrazol-induced amnesia and on seizure reactivity in rats". Methods and Findings in Experimental and Clinical Pharmacology. 17 (1): 53–8. PMID 7623521.

  • t
  • e
  • t
  • e

  • Retrieved from "https://en.wikipedia.org/w/index.php?title=Dotarizine&oldid=1204964893"

    Categories: 
    Drugs not assigned an ATC code
    Antimigraine drugs
    Calcium channel blockers
    Cyclizines
    Ketals
    Serotonin receptor antagonists
    Antihypertensive agent stubs
    Analgesic stubs
    Hidden categories: 
    Articles with short description
    Short description is different from Wikidata
    Articles with changed ChemSpider identifier
    Articles with changed EBI identifier
    Articles with changed InChI identifier
    Chemical pages without DrugBank identifier
    Articles without KEGG source
    Drugs with no legal status
    Drugboxes which contain changes to verified fields
    All stub articles
     



    This page was last edited on 8 February 2024, at 13:56 (UTC).

    Text is available under the Creative Commons Attribution-ShareAlike License 4.0; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc., a non-profit organization.



    Privacy policy

    About Wikipedia

    Disclaimers

    Contact Wikipedia

    Code of Conduct

    Developers

    Statistics

    Cookie statement

    Mobile view



    Wikimedia Foundation
    Powered by MediaWiki